Welcome to LookChem.com Sign In|Join Free
  • or
N-ACETYL-5-AMINOSALICYLIC ACID, also known as N-Acetyl Mesalazine, is a metabolite of Mesalazine and a derivative of Salicylic Acid. It is characterized by its light-brown crystalline appearance and possesses inhibitory properties against recombinant human thiopurine methyltransferase (hTPMT). N-ACETYL-5-AMINOSALICYLIC ACID plays a significant role in various applications across different industries due to its unique chemical properties and inhibitory functions.

51-59-2

Post Buying Request

51-59-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51-59-2 Usage

Uses

Used in Pharmaceutical Industry:
N-ACETYL-5-AMINOSALICYLIC ACID is used as a therapeutic agent for the treatment of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Its inhibitory action on hTPMT helps regulate the metabolism of certain drugs, reducing the risk of adverse effects and enhancing the efficacy of treatment.
Used in Research and Development:
N-ACETYL-5-AMINOSALICYLIC ACID is used as a research compound for studying the mechanisms of action and metabolic pathways of Mesalazine and other related drugs. Its role as an inhibitor of hTPMT makes it a valuable tool in understanding the enzyme's function and its impact on drug metabolism and efficacy.
Used in Diagnostic Applications:
N-ACETYL-5-AMINOSALICYLIC ACID is used as a diagnostic marker for monitoring the therapeutic response to Mesalazine treatment in patients with inflammatory bowel diseases. Its presence in the body can indicate the effectiveness of the treatment and help healthcare professionals make informed decisions regarding the management of the condition.
Used in Chemical Synthesis:
N-ACETYL-5-AMINOSALICYLIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those related to Salicylic Acid and its derivatives. Its unique chemical properties make it a valuable building block for the development of new drugs with potential applications in various therapeutic areas.

Check Digit Verification of cas no

The CAS Registry Mumber 51-59-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 1 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 51-59:
(4*5)+(3*1)+(2*5)+(1*9)=42
42 % 10 = 2
So 51-59-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H9NO4/c1-5(11)10-6-2-3-8(12)7(4-6)9(13)14/h2-4,12H,1H3,(H,10,11)(H,13,14)

51-59-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-acetamido-2-hydroxybenzoic acid

1.2 Other means of identification

Product number -
Other names Benzoic acid, 5-(acetylamino)-2-hydroxy-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51-59-2 SDS

51-59-2Synthetic route

5-Aminosalicylic Acid
89-57-6

5-Aminosalicylic Acid

acetic anhydride
108-24-7

acetic anhydride

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
With acetic acid In water for 0.5h; Reflux;94%
In water; acetone at 20℃; for 1.33333h; Reflux;94%
With multi-walled carbonnanotubes functionalized with phosphonic acid In neat (no solvent) at 20℃; for 0.333333h;90%
acetamide
60-35-5

acetamide

5-Aminosalicylic Acid
89-57-6

5-Aminosalicylic Acid

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
Stage #1: acetamide With thionyl chloride In diethyl ether
Stage #2: 5-Aminosalicylic Acid for 0.133333h; Heating;
84%
5-Aminosalicylic Acid
89-57-6

5-Aminosalicylic Acid

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
With acetic anhydride In water67%
Multi-step reaction with 2 steps
1: 36 h / 25 °C
2: NaOH / H2O / 2 h / 25 °C
View Scheme
5-acetylamino-2-bromobenzoic acid
22921-67-1

5-acetylamino-2-bromobenzoic acid

recorcinol
108-46-3

recorcinol

A

3-acetylaminobenzoic acid
587-48-4

3-acetylaminobenzoic acid

B

8-acetamide-3-hydroxy-6H-benzo-[c]-chromene-6-one

8-acetamide-3-hydroxy-6H-benzo-[c]-chromene-6-one

C

C15H13NO5

C15H13NO5

D

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
With lithium carbonate; copper(II) sulfate In water at 60℃; Reagent/catalyst; Temperature;A 15%
B 48%
C 11%
D 13%
5-nitrosalicylic acid
96-97-9

5-nitrosalicylic acid

A

5-Aminosalicylic Acid
89-57-6

5-Aminosalicylic Acid

B

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
With tin; acetic acid dann verduennt man mit Wasser und faellt mit Schwefelwasserstoff;
With tin; acetic acid
5-acetamido-2-acetoxybenzoic acid
6376-29-0

5-acetamido-2-acetoxybenzoic acid

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
With sodium hydroxide In water at 25℃; for 2h; Yield given;
5-nitrosalicylic acid
96-97-9

5-nitrosalicylic acid

acetic acid
64-19-7

acetic acid

tin

tin

A

5-Aminosalicylic Acid
89-57-6

5-Aminosalicylic Acid

B

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
5-(4'-sulphophenylazo)salicylic acid sodium salt

5-(4'-sulphophenylazo)salicylic acid sodium salt

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 71 percent / Na2S2O4; sodium hydroxide / H2O / 0.01 h / microwave irradiation
2.1: thionyl chloride / diethyl ether
2.2: 84 percent / 0.13 h / Heating
View Scheme
2-hydroxy-5-phenylazo-benzoic acid
3147-53-3

2-hydroxy-5-phenylazo-benzoic acid

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrosulfite sodium
2: alkali; water
View Scheme
salicylic acid
69-72-7

salicylic acid

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: glacial acetic acid; fuming nitric acid
2: tin; glacial acetic acid
View Scheme
Multi-step reaction with 2 steps
1: glacial acetic acid; lead nitrate
2: tin; glacial acetic acid
View Scheme
sebacoyl chloride
111-19-3

sebacoyl chloride

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

1,10-bis-5-acetamidosalicyl-sebacate
377064-84-1

1,10-bis-5-acetamidosalicyl-sebacate

Conditions
ConditionsYield
Stage #1: sebacoyl chloride; N-Acetyl-5-aminosalicylic acid With pyridine In tetrahydrofuran at 0℃; for 6.16667h;
Stage #2: With hydrogenchloride In tetrahydrofuran; water pH=2;
96%
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

C9H6(2)H3NO4

C9H6(2)H3NO4

Conditions
ConditionsYield
With 10% Pt/activated carbon; palladium 10% on activated carbon; hydrogen; water-d2 at 145℃; for 24h; Sealed tube; regioselective reaction;95%
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

N-butylamine
109-73-9

N-butylamine

5-acetamido-N-butylsalicylamide
6382-44-1

5-acetamido-N-butylsalicylamide

Conditions
ConditionsYield
Stage #1: N-Acetyl-5-aminosalicylic acid With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 0℃; for 0.5h;
Stage #2: N-butylamine In N,N-dimethyl-formamide at 0 - 20℃;
86%
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

1,2:5,6-di-O-isopropylidene-α-D-glucofuranose
582-52-5

1,2:5,6-di-O-isopropylidene-α-D-glucofuranose

3-O-N-acetyl-5-aminosalicylate-1,2:5,6-di-O-isopropylidene-D-glucofuranose

3-O-N-acetyl-5-aminosalicylate-1,2:5,6-di-O-isopropylidene-D-glucofuranose

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h; Cooling with ice;57%
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

1,2:3,4-di-O-isopropylidene-α-D-galactopyranose
4064-06-6

1,2:3,4-di-O-isopropylidene-α-D-galactopyranose

6-O-[5-(acetylamino)-2-hydroxybenzoyl]-1,2:3,4-di-O-isopropylidene-D-galactopyranose

6-O-[5-(acetylamino)-2-hydroxybenzoyl]-1,2:3,4-di-O-isopropylidene-D-galactopyranose

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h;51%
2,3;4,5-di-O-isopropylidene-β-D-fructopyranose
20880-92-6

2,3;4,5-di-O-isopropylidene-β-D-fructopyranose

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

1-O-[5-(acetylamino)-2-hydroxybenzoyl]-2,3:4,5-di-O-isopropylidene-D-fructopyranose

1-O-[5-(acetylamino)-2-hydroxybenzoyl]-2,3:4,5-di-O-isopropylidene-D-fructopyranose

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h;48%
2,3,4,5-di-O-isopropylidene-D-xylitol
30737-85-0

2,3,4,5-di-O-isopropylidene-D-xylitol

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

1-O-N-acetyl-5-aminosalicylate-2,3,4,5-di-isopropylidene-D-xylitol

1-O-N-acetyl-5-aminosalicylate-2,3,4,5-di-isopropylidene-D-xylitol

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h; Cooling with ice;47%
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

5-acetylamino-3-amino-2-hydroxy-benzoic acid

5-acetylamino-3-amino-2-hydroxy-benzoic acid

Conditions
ConditionsYield
With sulfuric acid; nitric acid man reduziert das Produkt mit Eisen und Essigsaeure;
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

2,6-dinitro-4-acetylaminophenol
118828-85-6

2,6-dinitro-4-acetylaminophenol

Conditions
ConditionsYield
With nitric acid
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

aniline
62-53-3

aniline

acetic acid-[4-hydroxy-3-(phenylimino-methyl)-anilide]

acetic acid-[4-hydroxy-3-(phenylimino-methyl)-anilide]

Conditions
ConditionsYield
With sodium hydroxide; boric acid; sodium chloride anschliessend Behandeln mit Natrium-Amalgam;
4-amino-2,3-dimethyl-1-phenylpyrazolin-5-one
83-07-8

4-amino-2,3-dimethyl-1-phenylpyrazolin-5-one

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

6-acetylamino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-benzo[e][1,3]oxazine-2,4-dione
14780-48-4

6-acetylamino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
propylamine
107-10-8

propylamine

N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

6-acetylamino-3-propyl-benzo[e][1,3]oxazine-2,4-dione
14780-41-7

6-acetylamino-3-propyl-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

NCI 50119
1925-98-0

NCI 50119

Conditions
ConditionsYield
With ammonia; triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

ethylamine
75-04-7

ethylamine

6-acetylamino-3-ethyl-benzo[e][1,3]oxazine-2,4-dione
14714-12-6

6-acetylamino-3-ethyl-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

phenethylamine
64-04-0

phenethylamine

6-acetylamino-3-phenethyl-benzo[e][1,3]oxazine-2,4-dione
14780-46-2

6-acetylamino-3-phenethyl-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

isopropylamine
75-31-0

isopropylamine

6-acetylamino-3-isopropyl-benzo[e][1,3]oxazine-2,4-dione
14780-42-8

6-acetylamino-3-isopropyl-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

1,1-dimethylhydrazine
57-14-7

1,1-dimethylhydrazine

6-acetylamino-3-dimethylamino-benzo[e][1,3]oxazine-2,4-dione
14780-50-8

6-acetylamino-3-dimethylamino-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

N,N-dimethylethylenediamine
108-00-9

N,N-dimethylethylenediamine

6-acetylamino-3-(2-dimethylamino-ethyl)-benzo[e][1,3]oxazine-2,4-dione
14780-43-9

6-acetylamino-3-(2-dimethylamino-ethyl)-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

N,N-diethylethylenediamine
100-36-7

N,N-diethylethylenediamine

6-acetylamino-3-(2-diethylamino-ethyl)-benzo[e][1,3]oxazine-2,4-dione

6-acetylamino-3-(2-diethylamino-ethyl)-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

4-Ethoxyaniline
156-43-4

4-Ethoxyaniline

6-acetylamino-3-(4-ethoxy-phenyl)-benzo[e][1,3]oxazine-2,4-dione
14780-47-3

6-acetylamino-3-(4-ethoxy-phenyl)-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

1-amino-2-propene
107-11-9

1-amino-2-propene

6-acetylamino-3-allyl-benzo[e][1,3]oxazine-2,4-dione
14792-97-3

6-acetylamino-3-allyl-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

methoxycarbonylmethylamine
616-34-2

methoxycarbonylmethylamine

(6-acetylamino-2,4-dioxo-4H-benzo[e][1,3]oxazin-3-yl)-acetic acid methyl ester
14780-49-5

(6-acetylamino-2,4-dioxo-4H-benzo[e][1,3]oxazin-3-yl)-acetic acid methyl ester

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

2,6-dimethylaniline
87-62-7

2,6-dimethylaniline

6-acetylamino-3-(2,6-dimethyl-phenyl)-benzo[e][1,3]oxazine-2,4-dione
14714-11-5

6-acetylamino-3-(2,6-dimethyl-phenyl)-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

methylamine
74-89-5

methylamine

6-acetylamino-3-methyl-benzo[e][1,3]oxazine-2,4-dione
14780-38-2

6-acetylamino-3-methyl-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine
N-Acetyl-5-aminosalicylic acid
51-59-2

N-Acetyl-5-aminosalicylic acid

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

5-diethylamino-2-pentylamine
140-80-7

5-diethylamino-2-pentylamine

6-acetylamino-3-(4-diethylamino-1-methyl-butyl)-benzo[e][1,3]oxazine-2,4-dione

6-acetylamino-3-(4-diethylamino-1-methyl-butyl)-benzo[e][1,3]oxazine-2,4-dione

Conditions
ConditionsYield
With triethylamine

51-59-2Relevant academic research and scientific papers

Scalable synthesis of 8-amino-3-hydroxy-6 H -benzo[ c ]chromen-6-one: Key intermediate for SEGRA via the Hurtley reaction

Kudo, Kazuhiro,Yamamoto, Noriyoshi

, p. 309 - 314 (2015)

A practical and scalable process for the preparation of 8-amino-3-hydroxy-6H-benzo[c]chromen-6-one in multihundred kilogram amounts has been developed. The key features of this synthesis are the application of the Hurtley reaction with a copper and base combination and the development of a purification process. The new synthesis improved the total yield from 49.0% to 59.5% and reduced the number of steps from three to two. Compared with the conventional medicinal route, manufacturing costs were reduced significantly by the use of inexpensive, easy to procure materials.

A Polymeric Drug for Treatment of Inflammatory Bowel Disease

Brown, Joseph P.,McGarraugh, Geoff V.,Parkinson, Thomas M.,Wingard, Robert E.,Onderdonk, Andrew B.

, p. 1300 - 1307 (1983)

Sulfasalazine (SASP) consists of salicylic acid azo linked at the 5-position to a pyridine-containing sulfonamide.This drug, currently used in inflammatory bowel disease treatment, is reductively cleaved by anaerobic bacteria in the lower bowel to 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP).Recent reports indicate that 5-ASA is the active therapeutic moiety and that SP is responsible for a variety of adverse clinical side effects.Water-soluble polymer 7, which contains salicylate residues azo linked at the 5-position to an inert polymer backbone, has been synthesized for the side-specific reductive release of 5-ASA in the lower bowel.Preparations of 7 deliver (chemical reduction) >1.96 mmol of 5-ASA/g of polymer.In vitro studies with the polymer in anaerobic rat cecal bacteria demonstrated a reduction rate of approximately 1 μequiv of azo bond h-1 (mL of cecal content)-1.A pharmacokinetic comparison of polymer and SASP showed similar deliveries of 5-ASA and metabolites to the lower bowel, blood and urine of orally dosed rats.Polymer 7 proved more active than SASP or 5-ASA in the guinea pigs ulcerative colitis model.Potential therapeutic advantages of 7 include nonabsorption/nonmetabolism in the small intestine, direct 5-ASA release at the disease site, and nonabsorption/nonmetabolism of the reduction-released carrier polymer.

Liposomal formulations of inflammatory bowel disease drugs: Local versus systemic drug delivery in a rat model

Kesisoglou, Filippos,Zhou, Simon Yuji,Niemiec, Susan,Lee, Jordan Wing,Zimmermann, Ellen M.,Fleisher, David

, p. 1320 - 1330 (2005)

Purpose. Based on adherence to intestinal mucosa, intralumenally administered liposomal formulations of 5-aminosalicylate (5-ASA) and 6-mercaptopurine (6-MP) were studied for their potential to enhance local drug delivery to intestinal tissue for the treatment of inflammatory bowel disease. Methods. 5-ASA was encapsulated in standard phospholipid liposomes while 6-MP required encapsulation in nonphospholipid liposomes to obtain equivalent drug loading. Encapsulation efficiency was measured by size-exclusion chromatography/high-performance liquid chromatogtaphy (HPLC). Liposomal formulations or solution of the drugs were injected into unligated jejunum to compare pharmacokinetics and into ligated loops of rat ileum and colon to evaluate local delivery. Dextran sulfate and acetic acid induced colitis were used as models of lower intestinal inflammation. Plasma, tissue and luminal drug and metabolite levels were measured by liquid scintillation counting or HPLC. Results. Encapsulation efficiency of 6-MP was dependent on lipid content and composition. While liposomal encapsulation significantly reduced systemic absorption of 5-ASA this was not the case for 6-MP. Liposomal adherence to intestinal tissue resulted in increased tissue levels for 5-ASA; however, 6-MP local tissue levels were not improved compared to solution drug. Conclusions. Nonphospholipid liposomes optimize encapsulation of 6-MP. While liposomal formulations show potential for local drug delivery to diseased bowel, drug physicochemical properties, absorption, and metabolic profiles dictate tissue-targeting potential. Liposomes reduce systemic availability from paracellular absorption of hydrophilic 5-ASA, but fail to improve local tissue delivery of 6-MP, a molecule absorbed by passive membrane permeation that undergoes extensive first- pass metabolism.

Synthesis and in vitro bioactivity evaluation of new glucose and xylitol ester derivatives of 5-aminosalicylic acid

Yousefi, Samira,Bayat, Saadi,Abdul Rahman, Mohd Basyaruddin,Ismail, Intan Safinar,Saki, Elnaz,Abdulmalek, Emilia

, p. 97295 - 97307 (2015)

New glucose and xylitol esters of 5-amino salicylic acid (5-ASA) were synthesized followed by evaluation of their in vitro antimicrobial, anti-cancer and anti-inflammatory activities. The results of the antimicrobial activity assessment revealed that the new final esters were more effective against Gram-negative as well as Gram-positive bacteria than the original drug. Furthermore, the new final products were confirmed by a cytotoxicity assay over HT-29 and 3T3 cell lines to be less toxic for normal cells compared to the initial drug. On the other hand, however, their suppressive effect against cancerous cells was somewhat lower. Meanwhile, the anti-inflammatory activity assay over a RAW264.7 macrophage cell line demonstrated that the NO inhibition activity of the conjugated drug to the previously mentioned saccharides, especially to glucose, has slightly improved compared to the non-conjugated drug. Finally, in silico screening was also performed in order to predict the potential interactions and binding energy of the novel products against cyclooxygenase (COX-1/COX-2) and lipoxygenase (5-LOX) proteins. Findings indicated that the new products had greater hydrogen bonds and binding affinities with the active sites of proteins towards 5-ASA.

Synthesis and in?vitro Bioactivity Evaluation of New Galactose and Fructose Ester Derivatives of 5-Aminosalicylic Acid

Yousefi, Samira,Bayat, Saadi,Rahman, Mohd Basyaruddin Abdul,Ibrahim, Zalikha,Abdulmalek, Emilia

, (2017/04/18)

Inflammatory bowel disease (IBD) is the main risk factor for developing colorectal cancer which is common in patients of all ages. 5-Aminosalicylic acid (5-ASA), structurally related to the salicylates, is highly active in the treatment of IBD with minor side effects. In this study, the synthesis of galactose and fructose esters of 5-ASA was planned to evaluate the role of glycoconjugation on the bioactivity of the parent drug. The antibacterial activity of the new compounds were evaluated against two Gram-negative and two Gram-positive species of bacteria, with a notable effect observed against Staphylococcus aureus and Escherichia coli in comparisons with the 5-ASA. Cytotoxicity testing over HT-29 and 3T3 cell lines indicated that the toxicity of the new products against normal cells was significantly reduced compared with the original drug, whereas their activity against cancerous cells was slightly decreased. The anti-inflammatory activity test in RAW264.7 macrophage cells indicated that the inhibition of nitric oxide by both of the monosaccharide conjugated derivatives was slightly improved in comparison with the non-conjugated drug.

The antioxidant properties of salicylate derivatives: A possible new mechanism of anti-inflammatory activity

Borges, Rosivaldo S.,Castle, Steven L.

supporting information, p. 4808 - 4811 (2015/10/28)

The synthesis and antioxidant evaluation by DPPH scavenging of a series of salicylic acid derivatives is described. Gentisic acid and its ester, amide, and amino analogs possess more radical scavenging capacity than salicylic acid and other salicylate derivatives. This property can possibly provide an additional pathway for anti-inflammatory activity through either single electron or hydrogen atom transfer, leading to a new strategy for the design of anti-inflammatory agents.

Preparation and characterization of multi-walled carbon nanotubes (MWCNTs), functionalized with phosphonic acid (MWCNTs-C-PO3H2) and its application as a novel, efficient, heterogeneous, highly selective and reusable catalyst for acetylation of alcohols, phenols, aromatic amines, and thiols

Dehghani, Farzaneh,Sardarian, Ali Reza,Doroodmand, Mohammad Mehdi

, p. 673 - 684 (2014/05/20)

A novel, efficient, heterogeneous, and reusable multi-walled carbon nanotubes (MWCNTs), functionalized with phosphonic acid (MWCNTs-C-PO 3H2) has been synthesized. The synthesized CNTs were characterized using some electron microscopic techniques such as scanning electron microscopy (SEM), atomic force microscopy (AFM), Energy dispersive X-ray spectroscopy (EDAX), and also some thermal and spectroscopic methods such as thermogravimetry (TG). The nitrogen adsorption behavior of the MWCNTs-C-PO3H2 catalyst was evaluated using the TG instrumentation system at 25°C. The catalyst was applied successfully for highly efficient and selective acetylation of alcohols, phenols, thiols and aromatic amines with acetic anhydride at room temperature under solvent-free conditions. The reusability of the catalyst was checked and the recovered catalyst was reused for five runs without significant loss in activity.

Iron-doped single-walled carbon nanotubes as new heterogeneous and highly efficient catalyst for acylation of alcohols, phenols, carboxylic acids and amines under solvent-free conditions

Sharghi, Hashem,Jokar, Mahboubeh,Doroodmand, Mohammad Mahdi

experimental part, p. 426 - 442 (2011/04/15)

Iron-doped single-walled carbon nanotubes (Fe/SWCNTs) represent an efficient and new heterogeneous reusable catalyst for the acylation of a variety of alcohols, phenols, carboxylic acids and amines with acid chlorides or acid anhydrides under solvent-free conditions. The reactions of various primary, secondary, tertiary, and benzylic alcohols, diols, phenols, as well as aromatic and aliphatic amines give acylated adducts in good to excellent yields.

Synthesis and characterization of metabolites and potential impurities of balsalazide disodium, an anti-inflammatory drug

Khan, Md. Umar,Baseer,Kumar, S. Ranjith,Saravanakumar,Prasannanjali,Gupta, P. Badarinadh,Kaushik, Vipin K.,Handa, Vijay K.,Islam, Aminul

experimental part, p. 2241 - 2253 (2010/10/02)

Balsalazide disodium (Colazide) is an oral prodrug of mesalamine (5-aminosalicylic acid) and possesses anti-inflammatory properties. During the process development for balsalazide disodium, we observed eight impurities, namely des-alanine balsalazide, balsalazide-alanine, balsalazide 3-isomer, decarboxy balsalazide, bis-azo salicylic acid, biphenyl-azo salicylic acid, bis-azo diacid, and bis-azo triacid. The present work describes the synthesis and characterization of these impurities. Copyrigh

Bisacetamide hydrochloride: A chemoselective and inexpensive N-acetylating reagent for aminophenols

Peng, Yanqing,Song, Gonghua,Ding, Fang

, p. 2021 - 2023 (2007/10/03)

A facile and chemoselective acetylation of aminophenols using bisacetamide hydrochloride under conventional heating and microwave irradiation has been developed. Also, a rapid method for the microwave-assisted preparation of aminophenols is described herein.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 51-59-2